Subsequent studies reported that patients with advanced GC with higher AP activity showed higher CD8A and PRF1 levels (CTL surface markers) and lower LAG-3 and TIM-3 levels, thus creating an inhibitory immune microenvironment and a mechanism for GC immune escape (154). The gene discussed is HAVCR2; the disease is gastric cancer.